Comparison of clinical cut-points and treatment targets for urine NTX and plasma βCTX-I in osteoporosis
详细信息 查看全文
- 作者：S.A. Paul Chubba ; b ; c ; Christine Mandelta ; Samuel Vasikarana ; b ; samuel.vasikaran@health.wa.gov.au" class="auth_mail" title="E-mail the corresponding author
- 关键词：p-βCTX-I ; plasma β isomerised carboxy-terminal telopeptides of type I collagen ; u-NTX ; urine amino-terminal telopeptides of type I collagen ; NTX/Cr ; u-NTX/creatinine ratio ; BCE ; bone collagen equivalent ; EDTA ; ethylenediaminetetraacetic acid ; ELISA ; enzyme-linked immunosorbent assay ; BTM ; markers of bone turnover ; BMD ; bone density ; IOF ; International Osteoporosis Foundation ; IFCC ; International Federation of Clinical Chemistry and Laboratory Medicine ; NBHA ; the National Bone Health Alliance ; s-
- 刊名：Clinical Biochemistry
- 出版年：2016
- 出版时间：May 2016
- 年：2016
- 卷：49
- 期：7-8
- 页码：529-533
- 全文大小：393 K
文摘
- m" id="list_l0005">
- •
Fracture outcome based treatment targets for bone turnover markers are lacking in the literature.
- •
We identified plasma βCTX-I values comparable to currently used urine NTX treatment targets for osteoporosis.
- •
We measured p-βCTX-I by 3 methods and uNTX in 146 patients and interpolated treatment targets from regression equations.
- •
The p-βCTX-I equivalent to the fracture outcome based uNTX treatment-target of 21 nmol BCE/mmol, is approximately 250 ng/L.
- •
This treatment target is lower than the mean of the reference interval for healthy premenopausal women.